Simon Sharmokh

LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO)

Sarah Sharman Moser, Alona Zer, Andre Hejazi, Netta Passwell et autres

Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2L+) patients with non-AGA non-squamous (NSQ) metastatic NSCLC (mNSCLC) …

LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO)

Sarah Sharman Moser, Alona Zer, Andre Hejazi, Netta Passwell et autres

Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2L+) patients with non-AGA non-squamous (NSQ) metastatic NSCLC (mNSCLC) …

LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli Health Maintenance Organization (HMO)

Sarah Sharman Moser, Alona Zer, Andre Hejazi, Netta Passwell et autres

BACKGROUND: Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2L+) patients with non-AGA non-squamous (NSQ) metastatic NSCLC …

il, us, ca (code pays fourni par la source)

LUMINATE-101-Maccabi: a real-world study of treatment patterns and clinical outcomes in patients with non-squamous metastatic non-small cell lung cancer in an Israeli health maintenance organization (HMO)

Sarah Sharman Moser, Alona Zer, Andre Hejazi, Netta Passwell et autres

Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1 L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2 L+) patients with non-AGA nonsquamous (NSQ) metastatic …

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

Kalatu Davies, Rajesh Kamalakar, Junhua Yu, Yinan Huang et autres

Introduction: Despite its association with promising clinical outcomes, chimeric antigen receptor T-cell (CAR T) therapy may not be a feasible treatment option for some patients with relapsed or refractory large B-cell lymphoma (LBCL). Although more patients have been referred to CAR T …

us (code pays fourni par la source)

EE458 Health Care Resource Utilization and Costs of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Claims Database Analysis in the US

Kalatu Davies, Rajesh Kamalakar, Yujun Huang, A Wang et autres

us (code pays fourni par la source)

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason M. Melear, Sudhir Manda et autres

Background: Venetoclax (VEN), a B-cell lymphoma 2 inhibitor, is an oral agent with demonstrated efficacy in patients (pts) with chronic lymphocytic leukemia (CLL). VEN treatment induces rapid tumor reduction, posing a risk for tumor lysis syndrome (TLS), particularly in pts with high …

us (code pays fourni par la source)

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

John F. Seymour, John G. Gribben, Matthew S. Davids, Anthony R. Mato et autres

Introduction: Venetoclax (Ven) has changed the chronic lymphocytic leukemia (CLL) treatment landscape with the ability to produce deep responses that result in improved long-term outcomes with well-tolerated fixed-duration regimens. Due to its potent pro-apoptotic effect on CLL cells, Ven poses a risk …

au, gb, us (code pays fourni par la source)

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Dandan Zheng, Kavita Sail, Lindsey E. Roeker, Beenish S. Manzoor et autres

Introduction: Venetoclax has demonstrated deep responses and sustained progression-free survival and is well tolerated in patients (pts) with previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) in clinical trials. Some early studies provided initial insight of venetoclax utilization in …

us, gb, de (code pays fourni par la source)

CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

Mary Ann Anderson, Matthew S. Davids, Arnon P. Kater, Tara Cochrane et autres

au, us, nl, tr, il, ca, ru, gb (code pays fourni par la source)

CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia

Jeff P. Sharman, David Andorsky, Jason M. Melear, Sudhir Manda et autres

us (code pays fourni par la source)

Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

Mary Ann Anderson, Matthew S. Davids, Arnon P. Kater, Tara Cochrane et autres

e20011 Background: Neutropenia is a common hematologic Grade (Gr) 3+ adverse event (AE) recorded in patients with chronic lymphocytic leukemia (CLL) receiving venetoclax (VEN). In this analysis, we evaluated fixed duration VEN monotherapy given to patients with relapsed or refractory (R/R) CLL …

au, us, nl, tr, il, ca, gb (code pays fourni par la source)